is excited to once again release Australia's most comprehensive medicinal cannabis "Product, Pricing and Patient Analysis".
2021 so far has been a year of milestones, with the last 6 months defined by a 50% surge in active patients to almost 70,000, as access, acceptance and average pricing continue to improve, and more Authorised Prescribers come onboard.
The marketplace is seeing more products than ever before, with 224 products now available - an increase of 18% since April 2021, but the pace of growth is slowing
In a positive sign for the sustainability of the industry, revenue from product sales for this year is forecast at $230M, up from an estimated $200+M in earlier projections, and the growth trajectory is expected to keep pace through 2022 with sales reaching over $400M.
This report will be the seventh major publication from FreshLeaf, which is the leading source of information, data and analysis on the sector.
KEY HIGHLIGHTS INCLUDE:
Market growth will exceed expectations in 2021 as active patients surge towards 100K
Revenue from product sales forecast at $230M at year end
Sharp uptick in SAS-B approvals coupled with ongoing growth in Authorised Prescribers suggests more mainstream acceptance by both patients and doctors
Product count continues to climb, an although the growth rate of new products is slowing
Oil remains the dominant product format but flower is gaining quickly in popularity
Growth in non-traditional delivery formats is stagnant
Average product price continues to drop although floor price lifts as new low-cost market entrants readjust pricing; wholesalers are given the squeeze
Average monthly spend continues slow downward trend; average daily dose increases
2022 will see continued sector transformation including improved patient access
Cassandra Hunt, Managing Director of FreshLeaf,
